| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Conway Vikki L | See "remarks" | Sell | 1,427 | $13.52 | $19,286.48 | -8.6% | +25.4% | +17.4% | |
| Mar 5, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 1,540 | $18.73 | $28,840.97 | -1.9% | -91.0% | -82.2% | |
| Mar 5, 2024 | ANIP Ani Pharmaceuticals Inc | Mutz Christopher | Head Of Rare Disease | Sell | 5,000 | $66.00 | $330,000.00 | -5.4% | -2.9% | -8.7% | |
| Mar 5, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Sell | 1,792 | $18.73 | $33,560.40 | -1.3% | -91.0% | -82.2% | |
| Mar 5, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 12,500 | $47.18 | $589,724.14 | -21.5% | -10.7% | -40.7% | |
| Mar 5, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 4,135 | $18.73 | $77,439.87 | -0.1% | -91.0% | -82.2% | |
| Mar 5, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 4,135 | $18.73 | $77,439.87 | -0.1% | -91.0% | -82.2% | |
| Mar 5, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 48,629 | $13.52 | $657,240.39 | -22.4% | +25.4% | +17.4% | |
| Mar 5, 2024 | PRGO Perrigo Co Plc | Ives Alison57 | EVP &Chief Scientific Officer | Buy | 2,490 | $27.26 | $67,877.40 | +18.3% | +1.4% | +8.1% | |
| Mar 5, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Sabag Mark | EVP, International Markets | Sell | 100,000 | $13.52 | $1,352,090.00 | -20.7% | +25.4% | +17.4% | |
| Mar 5, 2024 | VTRS Viatris Inc | Lyons Dillon Joellen | Director | Sell | 20,000 | $12.36 | $247,200.00 | -25.4% | -13.8% | -22.8% | |
| Mar 5, 2024 | VTRS Viatris Inc | Campbell Paul | See Remarks | Sell | 24,353 | $12.33 | $300,272.49 | -13.7% | -13.8% | -22.8% | |
| Mar 4, 2024 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 50,574 | $13.55 | $685,287.60 | -8.7% | +39.4% | +175.4% | |
| Mar 4, 2024 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | Director | Sell | 93,863 | $65.31 | $6,129,888.85 | -10.3% | +27.1% | +50.2% | |
| Mar 4, 2024 | IRWD Ironwood Pharmaceuticals Inc | Emany Sravan Kumar47 | SVP, Chief Financial Officer | Buy | 10,684 | $9.38 | $100,215.92 | +3.7% | -27.0% | -84.0% | |
| Mar 4, 2024 | LNTH Lantheus Holdings, Inc. | Leno Sam R | Director | Sell | 22,389 | $65.42 | $1,464,748.65 | -14.4% | +27.1% | +50.2% | |
| Mar 4, 2024 | SBFM Sunshine Biopharma Inc. | Slilaty Steve N. | Chief Executive Officer | Buy | 100,000 | $0.10 | $10,000.00 | +333.3% | -86.9% | -97.6% | |
| Mar 4, 2024 | ANIP Ani Pharmaceuticals Inc | Pera Antonio R58 | Director | Sell | 7,000 | $65.20 | $456,400.00 | -20.8% | -4.5% | -11.0% | |
| Mar 4, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Conway Vikki L | See "remarks" | Sell | 3,532 | $13.37 | $47,234.50 | -16.2% | +26.3% | +16.7% | |
| Mar 4, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Hughes Eric A | See "remarks" | Sell | 8,045 | $13.34 | $107,298.58 | -32.3% | +26.3% | +16.7% | |
| Mar 4, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 95,762 | $13.34 | $1,277,206.52 | -40.7% | +26.3% | +16.7% | |
| Mar 4, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Francis Richard D | President And CEO | Sell | 31,061 | $13.34 | $414,269.88 | -20.1% | +26.3% | +16.7% | |
| Mar 4, 2024 | VTRS Viatris Inc | Ni Xiangyang (sean)50 | President, Greater China | Sell | 21,532 | $12.51 | $269,313.97 | -10.4% | -14.4% | -24.2% | |
| Mar 4, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 15,915 | $232.83 | $3,705,423.33 | -34.7% | +20.8% | +34.9% | |
| Mar 4, 2024 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 20,677 | $14.32 | $296,135.52 | -79.0% | +39.4% | +175.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.